Evidence map›Paper›PMID 32605979›Full record

ArticlemBio2020

Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial.

William D Tolbert, Verna Van, Rebekah Sherburn, Marina Tuyishime, Fang Yan, Dung N Nguyen, Sherry Stanfield-Oakley, David Easterhoff, Mattia Bonsignori, Barton F Haynes and 5 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

William D Tolbert *Infectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Verna Van *Division of Vaccine Research of Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Rebekah SherburnInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Marina TuyishimeDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.ORCID 0000-0002-6940-3639
Fang YanDivision of Vaccine Research of Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Dung N NguyenInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Sherry Stanfield-OakleyDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
David EasterhoffDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Mattia BonsignoriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
M Anthony MoodyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Krishanu RayDivision of Vaccine Research of Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Guido FerrariDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
George K LewisDivision of Vaccine Research of Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Marzena PazgierInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA marzena.pazgier@usuhs.edu.
University of Maryland, Baltimore · USDuke University · USDuke Medical Center · USUniformed Services University of the Health Sciences · US

Funding

Physical Resources CoreP01AI120756 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2016 to 2020
$17.1M
Project 3- Mucosal Determinants of Virus TransmissionP01AI124912 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI GALLO, ROBERT C · 2016 to 2019
$14.4M
Unlocking Envelope: A New Strategy for a Functional Cure Through Antibody-Dependent Cell-Mediated CytotoxicityR01AI129769 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PAZGIER, MARZENA ELZBIETA · 2017 to 2021
$2.3M
Structural Targeting of Potentially Protective gp120 Epitopes in the C1/C2 RegionR01AI116274 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PAZGIER, MARZENA ELZBIETA · 2016 to 2019
$1.5M
Conformational Dynamics of HIV Envelope by Single Molecule SpectroscopyR01AI150447 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI RAY, KRISHANU · 2019 to 2019
$295k
NIAID NIH HHS P01 AI120756NIAID NIH HHS P01 AI124912NIAID NIH HHS R01 AI116274NIAID NIH HHS R01 AI129769NIAID NIH HHS R01 AI150447
6 · The paper itself

Abstract

Antibodies (Abs) specific for CD4-induced envelope (Env) epitopes within constant region 1 and 2 (C1/C2) were induced in the RV144 vaccine trial, where antibody-dependent cellular cytotoxicity (ADCC) correlated with reduced risk of HIV-1 infection. We combined X-ray crystallography and fluorescence resonance energy transfer-fluorescence correlation spectroscopy to describe the molecular basis for epitopes of seven RV144 Abs and compared them to A32 and C11, C1/C2 Abs induced in HIV infection. Our data indicate that most vaccine Abs recognize the 7-stranded β-sandwich of gp120, a unique hybrid epitope bridging A32 and C11 binding sites. Although primarily directed at the 7-stranded β-sandwich, some accommodate the gp120 N terminus in C11-bound 8-stranded conformation and therefore recognize a broader range of CD4-triggered Env conformations. Our data also suggest that Abs of RV144 and RV305, the RV144 follow-up study, although likely initially induced by the ALVAC-HIV prime encoding full-length gp120, matured through boosting with truncated AIDSVAX gp120 variants.

Indexed as

Antibody-Dependent Cell CytotoxicityAIDS VaccinesAmino Acid SequenceBinding Sites, AntibodyClinical Trials, Phase II as TopicCrystallography, X-RayDouble-Blind MethodEpitopes, T-LymphocyteFluorescence Resonance Energy TransferHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHumansRandomized Controlled Trials as TopicVaccine PotencyAIDS VaccinesEpitopes, T-LymphocyteHIV AntibodiesHIV Envelope Protein gp120human immunodeficiency virusRV144structural biologyvaccines

Identifiers

PMID32605979
PMCPMC7327165
OpenAlexW3038598096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.